日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer

PHAROS 研究最新结果的简明语言摘要：恩考拉非尼联合比美替尼治疗 BRAF V600E 突变型转移性非小细胞肺癌患者

期刊:Future Oncology
影响因子:2.6
doi:10.1080/14796694.2026.2645982
Johnson, Melissa L; Smit, Egbert F; Felip, Enriqueta; Ramalingam, Suresh S; Ahn, Myung-Ju; Tsao, Anne; Johnson, Bruce E; Offin, Michael; Hussein, Maen; Dagogo-Jack, Ibiayi; Goldman, Jonathan W; Clarke, Jeffrey M; Negrao, Marcelo V; Sanborn, Rachel E; Morgensztern, Daniel; Usari, Tiziana; Wilner, Keith; Alejandro, Linh; Rifi, Nada; Zhang, Xiaosong; Riely, Gregory J
肺癌
肿瘤
肿瘤免疫
BRAF
AROS
细胞生物学
发表日期：2026
文献求助 收藏

Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer

恩科拉非尼、西妥昔单抗和mFOLFOX6治疗BRAF突变型结直肠癌

期刊:New England Journal of Medicine
影响因子:78.5
doi:10.1056/NEJMoa2501912
Elez, Elena; Yoshino, Takayuki; Shen, Lin; Lonardi, Sara; Van Cutsem, Eric; Eng, Cathy; Kim, Tae Won; Wasan, Harpreet Singh; Desai, Jayesh; Ciardiello, Fortunato; Yaeger, Rona; Maughan, Timothy S; Morris, Van K; Wu, Christina; Usari, Tiziana; Laliberte, Robert; Dychter, Samuel S; Zhang, Xiaosong; Tabernero, Josep; Kopetz, Scott
BRAF
肿瘤
肠癌
肿瘤免疫
发表日期：2025
文献求助 收藏

Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

来自 PHAROS II 期研究的最新总生存期分析：恩考拉非尼联合比美替尼治疗 BRAF V600E 突变转移性非小细胞肺癌患者

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO-25-02023
Johnson, Melissa L; Smit, Egbert F; Felip, Enriqueta; Ramalingam, Suresh S; Ahn, Myung-Ju; Tsao, Anne; Johnson, Bruce E; Offin, Michael; Hussein, Maen; Dagogo-Jack, Ibiayi; Goldman, Jonathan W; Clarke, Jeffrey M; Negrao, Marcelo V; Sanborn, Rachel E; Morgensztern, Daniel; Usari, Tiziana; Wilner, Keith; Alejandro, Linh; Rifi, Nada; Zhang, Xiaosong; Riely, Gregory J
肺癌
肿瘤
肿瘤免疫
BRAF
AROS
细胞生物学
发表日期：2025
文献求助 收藏

Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report

Encorafenib联合Binimetinib治疗BRAF V600E突变转移性非小细胞肺癌患者的II期PHAROS研究的最新疗效和安全性简报

期刊:Journal of Thoracic Oncology
影响因子:20.8
doi:10.1016/j.jtho.2025.05.023
Riely, Gregory J; Ahn, Myung-Ju; Clarke, Jeffrey M; Dagogo-Jack, Ibiayi; Esper, Raymond; Felip, Enriqueta; Gelsomino, Francesco; Goldman, Jonathan W; Hussein, Maen; Johnson, Melissa; Marrone, Kristen A; Morgensztern, Daniel; Nadal, Ernest; Negrao, Marcelo V; Offin, Michael; Provencio, Mariano; Ramalingam, Suresh S; Roof, Logan; Sanborn, Rachel E; Smit, Egbert F; Tsao, Anne; Usari, Tiziana; Alcasid, Ann; Wilner, Keith; Tonkovyd, Svitlana; Zhang, Xiaosong; Johnson, Bruce E
肺癌
肿瘤
肿瘤免疫
BRAF
AROS
细胞生物学
发表日期：2025
文献求助 收藏

A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer

PHAROS 研究的简明语言摘要：恩考拉非尼联合比美替尼治疗 BRAF V600E 突变型转移性非小细胞肺癌患者

期刊:Future Oncology
影响因子:2.6
doi:10.2217/fon-2023-0859
Riely, Gregory J; Smit, Egbert F; Ahn, Myung-Ju; Felip, Enriqueta; Ramalingam, Suresh S; Tsao, Anne; Johnson, Melissa; Gelsomino, Francesco; Esper, Raymond; Nadal, Ernest; Offin, Michael; Provencio, Mariano; Clarke, Jeffrey; Hussein, Maen; Otterson, Gregory A; Dagogo-Jack, Ibiayi; Goldman, Jonathan W; Morgensztern, Daniel; Alcasid, Ann; Usari, Tiziana; Wissel, Paul; Wilner, Keith; Pathan, Nuzhat; Tonkovyd, Svitlana; Johnson, Bruce E
肺癌
肿瘤
肿瘤免疫
BRAF
AROS
细胞生物学
发表日期：2024
文献求助 收藏

Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC

克唑替尼治疗ROS1阳性晚期非小细胞肺癌东亚患者的II期研究的最终总生存期、安全性和生活质量结果

期刊:JTO Clinical and Research Reports
影响因子:3.5
doi:10.1016/j.jtocrr.2022.100406
Wu, Yi-Long; Lu, Shun; Yang, James Chih-Hsin; Zhou, Jianying; Seto, Takashi; Ahn, Myung-Ju; Su, Wu-Chou; Yamamoto, Noboru; Kim, Dong-Wan; Paolini, Jolanda; Usari, Tiziana; Iadeluca, Laura; Wilner, Keith D; Goto, Koichi
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2022
文献求助 收藏

Association of anticoagulant use with clinical outcomes from crizotinib in ALK- and ROS1-rearranged advanced non-small cell lung cancers: A retrospective analysis of PROFILE 1001

抗凝剂使用与克唑替尼治疗ALK和ROS1重排晚期非小细胞肺癌临床疗效的相关性：PROFILE 1001研究的回顾性分析

期刊:Cancer Medicine
影响因子:3.1
doi:10.1002/cam4.4789
Ng, Terry L; Tsui, David C C; Wang, Sherry; Usari, Tiziana; Patil, Tejas; Wilner, Keith; Camidge, David R
肺癌
肿瘤
肿瘤免疫
ALK
细胞生物学
发表日期：2022
文献求助 收藏

Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial

在亚洲国家入组的HER2阴性晚期乳腺癌且携带BRCA1/2种系突变的患者中，他拉唑帕尼与化疗的疗效比较：EMBRACA III期试验的探索性亚组分析

期刊:Cancer Research and Treatment
影响因子:3.8
doi:10.4143/crt.2020.1381
Lee, Kyung-Hun; Sohn, Joohyuk; Goodwin, Annabel; Usari, Tiziana; Lanzalone, Silvana; Im, Seock-Ah; Kim, Sung-Bae
肿瘤
HER2
肿瘤免疫
乳腺癌
BRCA1
发表日期：2021
文献求助 收藏

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

在携带胚系 BRCA1/2 突变、HER2 阴性的晚期乳腺癌患者中，他拉唑帕尼与化疗的疗效比较：EMBRACA 试验的最终总生存期结果

期刊:Annals of Oncology
影响因子:65.4
doi:10.1016/j.annonc.2020.08.2098
Litton, J K; Hurvitz, S A; Mina, L A; Rugo, H S; Lee, K-H; Gonçalves, A; Diab, S; Woodward, N; Goodwin, A; Yerushalmi, R; Roché, H; Im, Y-H; Eiermann, W; Quek, R G W; Usari, T; Lanzalone, S; Czibere, A; Blum, J L; Martin, M; Ettl, J
肿瘤
HER2
肿瘤免疫
乳腺癌
BRCA1
发表日期：2020
文献求助 收藏

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

克唑替尼治疗 ROS1 重排的晚期非小细胞肺癌 (NSCLC)：PROFILE 1001 研究的最新结果，包括总生存期

期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdz131
Shaw, A T; Riely, G J; Bang, Y-J; Kim, D-W; Camidge, D R; Solomon, B J; Varella-Garcia, M; Iafrate, A J; Shapiro, G I; Usari, T; Wang, S C; Wilner, K D; Clark, J W; Ou, S-H I
肺癌
肿瘤
肿瘤免疫
CLC
细胞生物学
发表日期：2019
文献求助 收藏